Japan Approves Eisai's Humira, Mitsubishi Tanabe's Remicade In Same-day Approval For Psoriasis
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Tokyo-headquartered Eisai and Osaka-based Mitsubishi Tanabe Pharma Jan. 20 simultaneously received Ministry of Health, Labor and Welfare approval to launch Japan's first fully human biological agents for the additional indication of psoriasis